Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib with or without ezetimibe for LDL-C lowering in adults with type 2 diabetes and/or metabolic syndrome
NL-OMON61029Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Jul 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia and hypercholesterolemia comparing Obicetrapib + ezetimibe fixed-dose combination, Obicetrapib monotherapy and Placebo (3 arms). Primary endpoints: Percent change in LDL-C from baseline to Day 84 versus placebo and Percent change in LDL-C from baseline to Day 84 for fixed-dose combination versus obicetrapib monotherapy. Started Jul 2026; status: active, not recruiting.
02
Drugs
obicetrapibezetimibe
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NL-OMON61029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61029.